Shares of Galectin Therapeutics Inc. (GALT) trade at a significant discount to their 52-week high of $7.13, recorded last December, and hover around $2 as the company prepares to present new data from its MASH cirrhosis trial.
Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis, formerly known as nonalcoholic steatohepatitis (NASH) cirrhosis, is the end stage of MASH, a type of liver disease. In MASH cirrhosis, scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH replace healthy liver tissue, preventing the liver from functioning normally.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.